# Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors With Statin for ACS Patients

Study · id `cardio:ct-nct07736313` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07736313](<https://clinicaltrials.gov/study/NCT07736313>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07736313

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT07736313. Non-randomized; no masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2028-09-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT07736313, source copy `cardio:ctgov-nct07736313-2026-07-30`, retrieved 2026-10-31)
- Planned start: 2026-07-01 (anticipated) (ClinicalTrials.gov record NCT07736313, source copy `cardio:ctgov-nct07736313-2026-07-30`, retrieved 2026-10-31)
- Primary completion: 2028-09-01 (anticipated) (ClinicalTrials.gov record NCT07736313, source copy `cardio:ctgov-nct07736313-2026-07-30`, retrieved 2026-10-31)
- Completion: 2029-09-01 (anticipated) (ClinicalTrials.gov record NCT07736313, source copy `cardio:ctgov-nct07736313-2026-07-30`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07736313-2026-07-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors With Statin for ACS Patients
- Condition: Acute Coronary Syndromes
- Intervention (Drug): PCSK9 inhibitor plus rosuvastatin 20 mg tab
- Intervention (Drug): Rosuvastatin 20 Mg Oral Tablet
- Lead sponsor: Assiut University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Assiut University (`cardio:org-assiut-university`)

## Provenance

Content hash: e37ddf2b4f51e08d7ce31d4669f3f005e1125b013e3f431bcf815c2e275868a0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
